Press Releases

September 28, 2017

Inova Partners with Veritas Genetics to Offer Whole Genome Sequencing and Interpretation

Inova announced today it has partnered with Veritas Genetics to provide whole genome sequencing and interpretation services. MyMap includes myGenome by Veritas and MediMap® pharmacogenomic testing by Inova; it also integrates Inova’s genetic counseling, research and clinical resources. MyMap will be available later this year.


August 3, 2017

Veritas Genetics Acquires Curoverse to Deploy Large-Scale Artificial Intelligence and Machine Learning in Genomics

BOSTON - August 3, 2017 - Veritas Genetics, the genome company, announces the acquisition of Boston-based Curoverse, the preeminent computing and bioinformatics company behind the Personal Genome Project (PGP) at Harvard Medical School, and creator of the open-source platform Arvados. Curoverse software is used by industry leaders such as the Wellcome Trust Sanger Institute to manage, process and share petabytes of genomic and biomedical data as well as facilitate AI and machine learning.


June 27, 2017

Veritas Genetics Is Named to MIT Technology Review’s Annual 50 Smartest Companies List

BOSTON, June 27, 2017 – For the second consecutive year, Veritas Genetics has been named to MIT Technology Review’s 2017 list of 50 Smartest Companies. As the only company to provide whole genome sequencing and interpretation to consumers and their physicians for the milestone price point of $1,000, Veritas continues to lead the genomics industry by relentlessly driving accessibility through advanced science and technology as well as increasing its global footprint.


June 15, 2017

Veritas Genetics Welcomes Dr. Robert C. Green and Dr. Natasha Y. Frank to its Medical & Scientific Advisory Board

BOSTON, June 15, 2017 /PRNewswire/ -- Veritas Genetics announces Robert C. Green, MD, MPH and Natasha Y. Frank, MD, FACMG, are now members of its distinguished Medical & Scientific Advisory Board. The two respected medical geneticists, known for their extensive experience in genomics, will join an existing team of leading experts who advise Veritas, the leader in accessible whole genome sequencing and interpretation. Both Dr. Green and Dr. Frank are board-certified, medical geneticists and physician scientists who serve as professors of medicine in the Division of Genetics at Brigham and Women's Hospital and Harvard Medical School.


June 1, 2017

Veritas Genetics Introduces the First Whole Genome Newborn Screening Test in China

BOSTON and HANGZHOU, China - June 1, 2017 - Veritas Genetics is launching the first whole genome newborn screening test in China, empowering parents and physicians to make more informed decisions regarding childhood onset diseases and medications. Veritas created myBabyGenome based on published insights and selected gene lists from the BabySeq Project, a multi-year NIH-funded study currently exploring the integration of sequencing in healthy newborns.


March 28, 2017

Veritas Genetics Collaborates with Dr. Steven Narod and Women’s College Hospital to Launch The Screen Project a Population-Based BRCA​ ​Screening Initiative across Canada

Veritas Genetics, the global leader in accessible genetic sequencing and interpretation, will provide BRCA testing for Canadian women and men who enroll in The Screen Project, a new Women’s College Hospital (WCH) initiative led by researchers in the Familial Breast Cancer Research Unit. By overcoming the current existing gaps in eligibility, WCH and Veritas will give Canadians unprecedented access to hereditary cancer screening. The goal is to enroll 10,000 participants within one year.


March 6, 2017

Veritas Genetics China Passes CAP & CLIA Inspections for Next Generation Sequencing

Veritas Genetics, the global leader in genetic sequencing and interpretation, announced that its laboratory located in Hangzhou, China has passed on-site inspection for the Laboratory Accreditation from the College of American Pathologists (CAP), and the lab is also now qualified for the CAP accreditation and CLIA certification.


February 8, 2017

Globally Renowned Molecular Genetics Expert, Birgit Funke, PhD, Joins Veritas Genetics as Vice President of Clinical Affairs

Veritas Genetics, the global leader in genetic sequencing and interpretation, welcomes Birgit Funke, PhD, FACMG as Vice President of Clinical Affairs. A board-certified clinical molecular geneticist, Funke is also an Associate Professor of Pathology at Harvard Medical School.


December 15, 2016

Veritas Genetics Adds Three Scientific Advisory Board Members to Accelerate Progress and Discovery in Consumer Genetics

​Veritas Genetics ​, a global leader in genetic sequencing and screening, welcomes three respected experts to its distinguished ​Scientific Advisory Board. ​ Chosen for their complementary perspectives and expertise in the fields of biomedical informatics, physiology and molecular genetics, the new members will contribute years of insight and a range of perspectives to the startup, which earlier this year, broke the $1,000 barrier for offering whole genome sequencing and interpretation to consumers, physicians and biomedical researchers.


October 17, 2016

Veritas Genetics Secures $30M in Series B Funding Expands Team with Strategic Hires to Drive Advancements in Whole Genome Sequencing

Veritas Genetics, a global leader in accessible genetic testing, announced $30 million in Series B funding from existing backer Lilly Asia Ventures and new investors Trustbridge Partners and Jiangsu Simcere Pharmaceutical.


July 11, 2016

VeritasGenetics China’s State-Of-The-Art R&D Center and Collaborations to Boost China Personalized Healthcare

VeritasGenetics, global leader in accessible genetic testing, held a grand opening ceremony for its Asia R&D center and business headquarters in Hangzhou, China, on July 8.


July 7, 2016

VeritasGenetics Recognized by Mit Technology Review for Advancing Access to Whole Genome Sequencing

VeritasGenetics, global leader in accessible genetic testing, was recognized by MIT Technology Review as one of the top “50 Smartest Companies 2016” in the world.


May 24, 2016

VeritasGenetics Partners with Pioneer Ranomics to Classify Variants of Uncertain Significance

VeritasGenetics, global leader in accessible genetic testing, is partnering with biotech startup Ranomics to uncover new insights about genetic variants of uncertain significance (VUS).


March 3, 2016

VeritasGenetics Launches $999 Whole Genome and Sets New Standard for Genetic Testing

VeritasGenetics, co-founded by Harvard Medical School professor and genetics pioneer Dr. George Church, today introduces Veritas myGenome, the world’s first whole genome for less than $1,000, including interpretation and genetic counseling.


February 22, 2016

VeritasGenetics and Worldcare Partnership First to Integrate Next Generation Whole Genome Sequencing and World-Class Medical Second Opinion Services

VeritasGenetics and WorldCare today announce a strategic partnership to integrate their next generation genetic testing with world-class medical second opinion services provided by the WorldCare Consortium.


January 6, 2016

VeritasGenetics Advances Access to Cancer Prevention with New Test for High-Risk Breast and Ovarian Cancer Patients

VeritasGenetics continues to advance hereditary breast and ovarian cancer (HBOC) prevention with the introduction of myBRCA HiRisk.


September 29, 2015

VeritasGenetics Breaks $1,000 Whole Genome Barrier

VeritasGenetics today announced that the company is making it possible for participants in the Personal Genome Project (PGP) to be among the first to get their whole genome sequenced and interpreted for less than $1,000.


September 15, 2015

VeritasGenetics Opens Asia R&D Center Dedicated to Addressing the Genetic Needs of Asian Populations

VeritasGenetics, a pioneer in improving the accessibility of genetic testing, is establishing an R&D center in the Hangzhou Economic & Technological Development Area (HEDA), Hangzhou, China, and expanding its China-based leadership team.


August 24, 2015

VeritasGenetics Receives European Ce Mark Approval for myBRCA Genetic Test for Hereditary Breast and Ovarian Cancer

Boston-based VeritasGenetics, a pioneer in accessible genetic screening for disease prevention and early detection, received its first European CE mark approval for the company’s hereditary breast and ovarian cancer genetic screening test, myBRCA.


June 1, 2015

VeritasGenetics to Advance Precision Medicine and Disease Prevention

Boston-based VeritasGenetics is launching its mission to disrupt the genetic testing industry and bring personalized medicine and prevention to the forefront, allowing individuals to take more control of their health.